NanoString, HalioDx Collaborate on Immunotherapy Response Assays | GenomeWeb

NEW YORK (GenomeWeb) – NanoString Technologies and French diagnostics firm HalioDx have signed a collaboration agreement to develop and commercialize several gene expression assays to assess response to cancer immunotherapy.

Under the terms of the agreement, the partners will jointly develop the assays on NanoString's nCounter platform. The assays will be based on research conducted by Jérôme Galon, HalioDx co-founder and researcher for France's Institut National de la Santé et de la Recherche Médicale. Both firms will commercialize the assays worldwide.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.

Sponsored by
Agilent Technologies

This webinar will provide specific use cases from a molecular pathology lab demonstrating how an automated bioinformatics pipeline can improve somatic variant assessment and reporting.

Sponsored by
Personal Genome Diagnostics

This online seminar will discuss the application of circulating tumor DNA (ctDNA) sequencing to evaluate the emergence of resistance mutations during therapy.